Overview

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depres

Status:
Recruiting

Trial end date:
2022-08-22

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to evaluate the efficacy of flexibly dosed esketamine nasal spray compared with quetiapine extended-release (XR), both in combination with a continuing selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI), in achieving remission in participants who have treatment-resistant major depressive disorder (MDD) with a current moderate to severe depressive episode.

Phase:

Phase 3

Details

Lead Sponsor:

Janssen-Cilag International NV

Treatments:

Esketamine
Norepinephrine
Quetiapine Fumarate
Serotonin
Serotonin Uptake Inhibitors